Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Investor Presentation (January 2024)
27 slides from Proteomics International Laboratories's investor presentation, Jan 25, 2024
Slide 1: ASX Release: Investor Presentation
ASX Release 25 January 2024 ASX code: PIQ Investor Presentation Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ) is pleased to release a copy of its latest investor presentation. Authorised by Dr Richard Lipscombe (Managing Director) and Mr Neville Gardiner
Slide 2: Proteomics International Investor Presentation
ASX: PIQ Proteomics International LABORATORIES LTD Investor Presentation 25 January 2024 Dr. Richard Lipscombe Managing Director 1
Slide 3: Disclaimer
Disclaimer ASX: PIQ This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in
Slide 4: Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd ASX: PIQ A medical technology company at the forefront of precision medicine and predictive diagnostics Three key focus tests driven by a proprietary platform technology: • Proven predictive test for early detection of diabetic kidney disease (DKD) • Being c
Slide 5: Corporate Overview
Corporate Overview ASX: PIQ Corporate Snapshot Financial and Corporate ASX code PIQ Market Capitalisation (Post January ‘24 Placement) A$111m • Top 40 Shareholders hold 54% Cash (31 Dec 2023 + Placement Proceeds) ~A$11m Share Price (24 Jan 2024) A$0.85 • Directors are highly aligned with shareholder
Slide 6: Board of Directors
Board of Directors ASX: PIQ Neville Gardiner BBus (Accounting and Business Law) (Curtin), Non-Executive Chair Seasoned finance professional with over 30 years’ experience providing corporate advice to Boards of public and private companies. South & He was Co-Founder and MD of Torridon Partners, an i
Slide 7: Promarker – Platform Technology
Promarker – Platform Technology ASX: PIQ PromarkerTM is a platform technology that can identify unique protein biomarkers ‘fingerprints’ The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics International to create novel diagnostic tests 6
Slide 8: Promarker D
Promarker D PROACTIVELY CHANGING RENAL HEALTHCARE Asimple blood test for predicting diabetic kidney disease
Slide 9: Problem and Solution – Diabetic Kidney Disease
Problem and Solution – Diabetic Kidney Disease ASX: PIQ Current standard-of-care diagnostics • Existing tests (known as eGFR and ACR) can only detect chronic kidney disease once it is already present • Current standard-of-care tests cannot predict the onset Roadblock of diabetic kidney disease The P
Slide 10: PromarkerD: World Class Advisory Board
PromarkerD: World Class Advisory Board ASX: PIQ Proteomics International is supported by an international, highly acclaimed advisory board Professor Tim Davis MedSc, MB, W.Aust., DPhil Oxf., Associate Professor Michael Shanik MD, FACP, FACE FRACP, MRCP (UK) – Australia – United States Consultant phy
Slide 11: PromarkerD – Simple Integration & Use
PromarkerD – Simple Integration & Use ASX: PIQ Blood sample drawn Biomarkers analysed Results generated by Results and intervention plan PromarkerD Hub software delivered Sample is drawn at clinic or Laboratory uses a standard Cloud based algorithm, the Clinician delivers results to patient patholog
Slide 12: PromarkerD – Results & Intervention
PromarkerD – Results & Intervention ASX: PIQ How PromarkerD results are delivered LOW RISK MODERATE RISK HIGH RISK RISK SCORE % 0 10 20 100 Prognostic 16% indicates a moderate risk of decline in kidney function* Risk Score Intervention Testing Regimen Low Risk • Standard diabetes management Test Ann
Slide 13: PromarkerD in the Clinic
PromarkerD in the Clinic ASX: PIQ Peer Reviewed Physician Support Outperforms Standard of Care PromarkerD tested on over 5,000 Survey of 400 Endocrinologists & • 857 community based patients tested for patients in 4-year clinical studies Primary Care Physicians (US based) existing DKD at baseline: 4
Slide 14: PromarkerD: Precision Medicine
PromarkerD: Precision Medicine ASX: PIQ The Need The Treatments The Utility There is a significant and growing need for Patients identified as high-risk of DKD by Complementary diagnostic intervention for diabetic kidney disease (DKD) PromarkerD now have multiple preventative Early diagnosis of DKD
Slide 15: PromarkerD - Patented in all Major Markets
PromarkerD - Patented in all Major Markets ASX: PIQ Diabetic Kidney Disease is becoming one of the largest burdens on healthcare systems globally Patent family & Trademark covers 72% of world’s diabetics1 45% Country Patent/Application No Patent Status No. Diabetics1 undiagnosed Australia 2011305050
Slide 16: United States: Commercialisation in Progress
United States: Commercialisation in Progress ASX: PIQ Sonic Healthcare USA has the exclusive licence to commercialise PromarkerD in the world’s largest healthcare market Over 7,000 Employees Over 300 Sales reps Over 400 pathologists Services over 20 million patients Marketing, Sample collection, Rep
Slide 17: Reimbursement in the US
Reimbursement in the US ASX: PIQ Proteomics International has worked with its partner Sonic Healthcare USA to achieve reimbursement in the US CMS is the federal agency Medicare and Medicaid CMS is responsible for CMS has assigned a in the United States that collectively responsible for providing hea
Slide 18: Target Markets: PromarkerD
Target Markets: PromarkerD ASX: PIQ Proteomics International is showcasing PromarkerD with KoL’s at major conferences globally • Distribution Licence with Apacor Ltd for PromarkerD Next Steps • Test registered with Medicines & Healthcare products • Engagement with the NHS Supply Chain Tender Regulat
Slide 19: Pipeline of Precision Diagnostics
Pipeline of Precision Diagnostics ASX: PIQ Platform technology drives deep pipeline of novel diagnostic tests Further global potential in new markets • Promarker platform develops novel intellectual property • Targeting new diagnostic tests in areas of significant unmet need • Enormous markets and r
Slide 20: Dx Pipeline: Endometriosis
Dx Pipeline: Endometriosis ASX: PIQ Potential world-first blood test in late-stage development Impact of Endometriosis • Endometriosis is a common and painful disease where uterus tissue grows into other organs • Currently diagnosis takes an average of 7.5 years and requires invasive surgery (laparo
Slide 21: Dx Pipeline: Oesophageal Cancer
Dx Pipeline: Oesophageal Cancer ASX: PIQ Potential world-first blood test in late-stage development Impact of Oesophageal Cancer • 1 in 20 cancer deaths worldwide due to oesophageal cancer - 5 year survival rate < 20% • Currently diagnosis requires a specialist endoscopy procedure; treating the dise
Slide 22: Dx Pipeline: Oxidative Stress
Dx Pipeline: Oxidative Stress ASX: PIQ Potential world-first blood test in late-stage development What is Oxidative Stress? Broad applications of OxiDx technology: • Oxidative stress occurs when the body’s ➢ Athletic monitoring tool for competition preparedness: antioxidant defences are overwhelmed
Slide 23: Timeline & Milestones
Timeline & Milestones ASX: PIQ FY23 Announcements & Achievements FY24 Targets & Achievements 29 Aug 2022 14 Dec 2022 Generate sales revenue for 1 Aug 2022 OxiDx P/L spin- UK NICE 29 Sept, 1 Jan 2024 PromarkerD in the USA Potential breakthrough out launched for publishes 3 May 2023 PromarkerD blood t
Slide 24: Value Inflection Points
Value Inflection Points ASX: PIQ Share Price Catalysts throughout FY24 Exceptional Global Opportunity Milestone Qtr Dec Mar Jun Impact ➢ Disruptive, cutting-edge technology & proven in-house diagnostics platform PromarkerD First Sales in USA Initiate pathway to significant revenues ➢ PromarkerD test
Slide 25: Contact
Contact ASX: PIQ Dr Richard Lipscombe Dirk van Dissel Managing Director Investor Relations & Corporate Advisor T: +61 8 9389 1992 Candour Advisory E: enquiries@proteomicsinternational.com T: +61 408 326 367 www.proteomicsinternational.com E: dirk@candouradvisory.com.au Kyle Moss Corporate Advisor Eu
Slide 26: Supplemental
Supplemental ASX: PIQ 25
Slide 27: PromarkerD: Key Publications
PromarkerD: Key Publications ASX: PIQ PromarkerD Demonstrates Benefit of Peters KE, et al. Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Score. J Clinical Early Treatment with SGLT2-inhibitors Medicine. 2023. Fusfeld L, et al. Evaluation of the clinical utility of the P
Proteomics International Laboratories — Investor Presentation (January 2024) on 6ix